Your browser doesn't support javascript.
loading
[Small-cell carcinoma of the prostate: A report of 2 cases and review of the literature].
Wang, Zhi-Chao; Lin, Rong-Wu; Zhou, Jian-Fu; Gui, Ze-Hong; Wang, Shu-Sheng; Chen, Zhi-Qiang; Xiang, Song-Tao.
Afiliação
  • Wang ZC; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
  • Lin RW; The Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China.
  • Zhou JF; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
  • Gui ZH; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
  • Wang SS; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
  • Chen ZQ; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
  • Xiang ST; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China.
Zhonghua Nan Ke Xue ; 25(2): 150-153, 2019 Feb.
Article em Zh | MEDLINE | ID: mdl-32216202
ABSTRACT

OBJECTIVE:

To investigate the clinicopathological characteristics and improve the clinical treatment of prostatic small-cell carcinoma (PSCC).

METHODS:

We reported 2 cases of PSCC derived from prostate cancer after treated by androgen blockade and prostate electrotomy and reviewed the relevant literature.

RESULTS:

Two patients with PSA elevation were diagnosed with prostate cancer by prostatic puncture biopsy and treated by maximum androgen blockade, which reduced their total PSA to the normal level. Later, due to difficult urination, they both underwent prostate electrotomy, followed by chemotherapy or radiotherapy for PSCC confirmed by postoperative pathology. Nevertheless, they died at 8 to 9 months after the discovery of PSCC.

CONCLUSIONS:

PSCC can derive from prostate cancer after treatment, which may be attributed to the pathological mutation induced by long-term endocrine therapy. PSCC is more malignant than prostate cancer, and its prognosis is poor.
Assuntos
Palavras-chave
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Carcinoma de Células Pequenas Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: Zh Ano de publicação: 2019 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Carcinoma de Células Pequenas Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: Zh Ano de publicação: 2019 Tipo de documento: Article